PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

Description: PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData predicts that market share for private vaccine manufacturers to virtually disappear over the course of the forecast, with Brazil unleashing domestically-produced MenC conjugate vaccines that are more cost-effective for the government-funded healthcare system. These vaccines, which include a MenC conjugate vaccine and a heptavalent pediatric vaccine (DTP-Hib-HepB-IPV-MenC) are being developed and produced by government-sponsored institutions such as Bio-Manguinhos, Instituto Butantan, Fiocruz, and FUNED. Once they become widely available, these vaccines will quickly steal market share from private manufacturers because of their cost-effectiveness advantage.

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Brazil from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Brazil Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Brazil

Contents:

1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Meningococcal Immunization Policy
4.2 Brazil
4.2.1 Meningococcal Immunization Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles – Major Brands
5.3.1 Meningitec
5.3.2 Menjugate
5.3.3 NeisVac-C
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Unmet Need: Protection Against Serogroup B Disease
6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine
6.2.3 Unmet Need: More Cost-Effective Vaccines
6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents
6.2.5 Unmet Need: Immunogenic Infant Vaccines
6.2.6 Unmet Need: Improved Vaccination Coverage Rates
6.2.7 Unmet Need: Increased Patient Awareness and Education
6.3 Unmet Needs Gap Analysis
6.4 Opportunities
6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations
6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants
6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets
7 Pipeline Assessment
7.1 Overview
7.2 Promising Vaccines in Clinical Development
7.3 Promising Vaccines in Early Clinical Development
7.3.1 MenC conjugate
7.3.2 Heptavalent DTP-Hib-HepB-IPV-MenC
8 Market Outlook
8.1 Brazil
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccine Approval vs. Routine Schedule Inclusion
9.4.3 Vaccines Included
9.4.4 General Pricing Assumptions
9.4.5 Individual Vaccine Assumptions
9.5 Physicians and Specialists Included in this Study
9.6 About the Authors
9.6.1 Authors
9.6.2 Reviewers
9.6.3 Global Head of Healthcare
9.7 About Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Meningococcal Disease
Table 2: Meningococcal Immunization Recommendation Agencies by Country
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012
Table 4: Leading Vaccines for Meningococcal Disease, 2012
Table 5: Product Profile – Meningitec
Table 6: Meningitec SWOT Analysis, 2012
Table 7: Product Profile – Menjugate
Table 8: Menjugate SWOT Analysis, 2012
Table 9: Product Profile – NeisVac-C
Table 10: NeisVac-C SWOT Analysis, 2012
Table 11: Overall Unmet Needs – Current Level of Attainment
Table 12: Clinical Unmet Needs – Gap Analysis, 2012
Table 13: Product Profile – MenC conjugate
Table 14: MenC conjugate SWOT Analysis, 2012
Table 15: Product Profile – Heptavalent DTP-Hib-HepB-IPV-MenC
Table 16: Heptavalent DTP-Hib-HepB-IPV-MenC SWOT Analysis, 2012
Table 17: Sales Forecasts ($m) for Meningococcal Vaccines in Brazil, 2012–2022
Table 18: Key Events Impacting Sales for Meningococcal Vaccines in Brazil, 2012–2022
Table 19: Brazil Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022
Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Membrane Structure of N. meningitidis
Figure 2: Sales for Meningococcal Vaccines in Brazil by Vaccine Class, 2012–2022

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/2588292/](http://www.researchandmarkets.com/reports/2588292/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2588292/">http://www.researchandmarkets.com/reports/2588292/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6I5RV3</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Number of Users</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

- Pay by check: Please post the check, accompanied by this form, to:
  
  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.

- Pay by wire transfer: Please transfer funds to:
  
  Account number: 833 130 83
  Sort code: 98-53-30
  Swift code: ULSBIE2D
  IBAN number: IE78ULSB98533083313083
  Bank Address: Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World